152 related articles for article (PubMed ID: 37933476)
21. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
22. Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer Locations.
Li G; Liao CY; Chen JZ; Huang L; Yang C; Tian YF; Wang YT; Du Q; Zhan Q; Chen YL; Chen S
Front Oncol; 2021; 11():646082. PubMed ID: 33968745
[TBL] [Abstract][Full Text] [Related]
23. Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Yamaue H
Ann Surg Oncol; 2021 Mar; 28(3):1521-1532. PubMed ID: 32705517
[TBL] [Abstract][Full Text] [Related]
24. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
25. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy.
Song KB; Kwon J; Kim YW; Hwang DW; Lee JH; Hong S; Lee JW; Hwang K; Yoo D; Kim SC
J Hepatobiliary Pancreat Sci; 2019 Jun; 26(6):227-234. PubMed ID: 30980486
[TBL] [Abstract][Full Text] [Related]
27. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Gulhati P; Prakash L; Katz MHG; Wang X; Javle M; Shroff R; Fogelman D; Lee JE; Tzeng CD; Lee JH; Weston B; Tamm E; Bhosale P; Koay EJ; Maitra A; Wang H; Wolff RA; Varadhachary GR
Ann Surg Oncol; 2019 Feb; 26(2):619-627. PubMed ID: 30324485
[TBL] [Abstract][Full Text] [Related]
28. Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Adenocarcinoma of the Body and Tail.
Mizumoto T; Toyama H; Asari S; Terai S; Mukubo H; Yamashita H; Shirakawa S; Nanno Y; Ueda Y; Sofue K; Tanaka M; Kido M; Ajiki T; Fukumoto T
Ann Surg Oncol; 2018 Mar; 25(3):638-646. PubMed ID: 29264672
[TBL] [Abstract][Full Text] [Related]
29. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
30. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
31. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study.
Satoi S; Yamamoto T; Uchida K; Fujii T; Kin T; Hirano S; Hanada K; Itoi T; Murakami Y; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Shimokawa T; Yamaue H; Okazaki K;
Pancreas; 2020 Jul; 49(6):837-844. PubMed ID: 32590619
[TBL] [Abstract][Full Text] [Related]
32. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
[TBL] [Abstract][Full Text] [Related]
33. Impact of Preoperative Tumor Size on Prognosis of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinomas.
Miyata Y; Yonamine N; Fujinuma I; Tsunenari T; Takihata Y; Hakoda H; Nakazawa A; Iwasaki T; Einama T; Togashi J; Tsujimoto H; Ueno H; Beck Y; Kishi Y
Ann Surg Oncol; 2023 Dec; 30(13):8621-8630. PubMed ID: 37658273
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.
Fukumoto T; Watanabe T; Hirai I; Kimura W
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):472-9. PubMed ID: 27246905
[TBL] [Abstract][Full Text] [Related]
35. Impact of the transection plan on postoperative pancreatic fistulas occurring after robot-assisted distal pancreatectomy for nonmalignant pancreatic neoplasms.
Qian L; Hu B; Wang J; Lu X; Deng X; Chai W; Xu Z; Wang W; Shen B
Surg Endosc; 2023 Jan; 37(1):309-318. PubMed ID: 35941312
[TBL] [Abstract][Full Text] [Related]
36. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma.
Malleo G; Maggino L; Nobile S; Casciani F; Cacciatori N; Paiella S; Luchini C; Rusev B; Capelli P; Marchegiani G; Bassi C; Salvia R
Eur J Surg Oncol; 2020 Sep; 46(9):1734-1741. PubMed ID: 32327367
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
38. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
39. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
40. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
